| Literature DB >> 31948471 |
Kelly L Wyres1, To N T Nguyen2, Margaret M C Lam1, Louise M Judd1, Nguyen van Vinh Chau3, David A B Dance4,5,6, Margaret Ip7, Abhilasha Karkey5,8, Clare L Ling5,9, Thyl Miliya10, Paul N Newton4,5,6, Nguyen Phu Huong Lan3, Amphone Sengduangphachanh4, Paul Turner5,10, Balaji Veeraraghavan11, Phat Voong Vinh2, Manivanh Vongsouvath4, Nicholas R Thomson6,12, Stephen Baker13, Kathryn E Holt1,6.
Abstract
BACKGROUND: Klebsiella pneumoniae is a leading cause of bloodstream infection (BSI). Strains producing extended-spectrum beta-lactamases (ESBLs) or carbapenemases are considered global priority pathogens for which new treatment and prevention strategies are urgently required, due to severely limited therapeutic options. South and Southeast Asia are major hubs for antimicrobial-resistant (AMR) K. pneumoniae and also for the characteristically antimicrobial-sensitive, community-acquired "hypervirulent" strains. The emergence of hypervirulent AMR strains and lack of data on exopolysaccharide diversity pose a challenge for K. pneumoniae BSI control strategies worldwide.Entities:
Keywords: Bloodstream infection; Capsule types; Genomic surveillance; Hypervirulent; Klebsiella pneumoniae; MDR
Mesh:
Substances:
Year: 2020 PMID: 31948471 PMCID: PMC6966826 DOI: 10.1186/s13073-019-0706-y
Source DB: PubMed Journal: Genome Med ISSN: 1756-994X Impact factor: 11.117
Fig. 1Klebsiella pneumoniae BSI isolates included in this study. a Collection sites and countries of origin for all Klebsiella pneumoniae complex isolates for which genome data were available. b Years of collection coloured by country of origin as in panel a. c Chromosomal multi-locus sequence types (STs) of Klebsiella pneumoniae sensu stricto isolates (only STs accounting for > 1% isolates are shown, coloured by country of origin as in panel a)
Novel virulence plasmids sequenced in this study and their host isolate properties
| Isolate | Virulence plasmid (accession) | AMR genes | AMR genes elsewhere in genome | |
|---|---|---|---|---|
| Sample data and chromosomal typing | ||||
| Size and | ||||
2579 Nepal, 2016 ST15, KL112, ICE | p2579_1 (MK649822) 182,805 bp IncHI1B | |||
BA6740 India, 2016 ST11, KL24, ICE | pBA6740_1 (MK649823) 226,590 bp IncFIB(pQIL), IncFIIK | |||
BA813 India, 2017 ST2096, KL64, ICE | pBA813_1 (MK649825) 273,676 bp IncFIB(Mar), IncFIB | |||
BA6201 India, 2017 ST231, KL51, ICE | pBA6201_1 (MK649824) 195,016 bp IncFIA, IncFIB(pQIL), IncFIIK, IncFII | |||
16114547 Laos, 2016 ST290, KL21 | p16114547_1 (MK649829) 187,989 bp IncFIBK, IncFII | |||
1675474 Laos, 2015 ST7-1LV, KL54 | p1675474_1 (MK649827) 181,647 bp IncFIBK, IncFII | |||
1675479 Laos, 2015 ST945-2LV, KL125 | p1675479_1 (MK649828) 167,992 bp IncFIBK, IncFII | |||
130411–38618 Vietnam, 2011 ST17, KL127 | p130411-38,618_1 (MK649826) 241,799 bp IncFIBK, IncFIIK |
*rep types as per the PlasmidFinder v2.0 database are shown. All plasmids carried the iuc aerobactin synthesis operon. No plasmids carried the iro or rmpA/rmpA2 virulence loci. Seven virulence plasmids also carried AMR (antimicrobial resistance) genes. Seven host isolates harboured additional AMR genes elsewhere in the genome. ST chromosomal multi-locus sequence type, KL K-locus. ^Inexact match
Comparison of key features of Klebsiella genomes from South and Southeast Asian sites
| S Asia | SE Asia | OR | LCI | UCI | |||
|---|---|---|---|---|---|---|---|
| | 100 (98%) | 87 (87%) | 0.011 | 0.13 | 0.01 | 0.62 | * |
| | 1 (1%) | 4 (4%) | 0.838 | 4.18 | 0.40 | 209.04 | |
| | 1 (1%) | 0 (0%) | na | na | na | na | |
| | 0 (0%) | 9 (9%) | na | na | na | na | |
| Features of | |||||||
| | |||||||
| ST15 | 11 (11%) | 15 (17%) | 1.158 | 1.68 | 0.67 | 4.32 | |
| ST14 | 16 (16%) | 2 (2%) | 0.008 | 0.12 | 0.01 | 0.56 | ** |
| ST23 | 2 (2%) | 12 (14%) | 0.015 | 7.76 | 1.65 | 73.39 | * |
| ST231 | 17 (17%) | 0 (0%) | 5.14 × 10−5 | 0.00 | 0.0 | 0.24 | ** |
| | |||||||
| KL1 | 2 (2.5%) | 13 (15%) | 0.012 | 6.70 | 1.44 | 63.22 | * |
| KL2 | 4 (5.1%) | 11 (13%) | 0.216 | 2.70 | 0.76 | 12.15 | |
| | |||||||
| Multi-drug resistant (≥ 3 acquired classes) | 81 (81%) | 44 (51%) | 1.06 × 10−4 | 0.24 | 0.12 | 0.48 | ** |
| Aminoglycosides | 76 (76%) | 41 (47%) | 0.001 | 0.28 | 0.14 | 0.55 | ** |
| Fluoroquinolones | 80 (80%) | 39 (45%) | 7.13 × 10−6 | 0.21 | 0.10 | 0.41 | ** |
| Phenicols | 27 (27%) | 25 (29%) | 7.833 | 1.09 | 0.55 | 2.17 | |
| Sulfonamides | 63 (63%) | 42 (48%) | 0.493 | 0.55 | 0.29 | 1.02 | |
| Tetracyclines | 24 (24%) | 39 (45%) | 0.029 | 2.56 | 1.32 | 5.05 | * |
| Trimethoprim | 62 (62%) | 38 (44%) | 0.118 | 0.48 | 0.25 | 0.89 | |
| 3rd-generation cephalosporins (ESBL) | 60 (60%) | 41 (47%) | 0.949 | 0.60 | 0.32 | 1.11 | |
| Carbapenems | 47 (47%) | 1 (1%) | 7.13 × 10−13 | 0.01 | 0.0 | 0.08 | ** |
| | |||||||
| Yersiniabactin ( | 65 (65%) | 46 (53%) | 0.205 | 0.61 | 0.32 | 1.13 | |
| Aerobactin ( | 27 (27%) | 32 (37%) | 0.319 | 1.57 | 0.81 | 3.07 | |
| | |||||||
| | 13 (13%) | 27 (31%) | 0.012 | 2.99 | 1.36 | 6.86 | * |
| | 0 (0%) | 5 (6%) | 0.061 | na | 1.08 | inf | |
| | 12 (12%) | 0 (0%) | 0.001 | 0.00 | 0.0 | 0.8 | ** |
| | |||||||
| ESBL and | 45 (45%) | 26 (30%) | 0.144 | 0.52 | 0.27 | 0.99 | |
| ESBL and | 16 (16%) | 1 (1%) | 0.001 | 0.06 | 0.0 | 0.41 | ** |
| CP and | 37 (37%) | 1 (1%) | 1.79 × 10− 10 | 0.02 | 0.0 | 0.13 | ** |
| CP and | 13 (13%) | 0 (0%) | na | na | 0.0 | 0.34 | |
*South (S) Asia is represented by the two sites in India and Nepal, isolated 2016–2017; Southeast (SE) Asia is represented by the sites in Cambodia, Laos, Thailand and Vietnam, isolated 2015–2016. p values were calculated using Fisher’s exact test for differences in the prevalence of each feature (in rows) for the S vs SE Asia samples and are adjusted using Bonferroni correction for the number of tests within each group of comparisons (as labelled in italics; sample size for each are also in italics). na test not applicable (one or more values equal to zero). Inf infinity, OR odds ratio, LCI and UCI, lower and upper bounds for 95% confidence interval, respectively. *p < 0·05, **p < 0·01
Fig. 2Cumulative K and O locus prevalence by location. a Cumulative prevalence of K-loci ordered by mean prevalence across all locations (highest to lowest, see Additional file 2: Table S3). b Cumulative prevalence of predicted O-types ordered by mean prevalence across all locations (highest to lowest, see Additional file 2: Table S4). Note that the Thai sampling site is excluded due to small sample size (n = 4)
Fig. 3Prevalence of antimicrobial resistance determinants among K. pneumoniae sensu stricto isolates. a Density plots showing the distributions of number of drug classes for which acquired resistance determinants were detected in each genome (n = total genomes by location). Grey shading indicates multi-drug resistance (≥ 3 resistance classes). b Proportion of genomes for which extended-spectrum beta-lactamase genes were detected (% ESBL+). c Proportion of genomes for which carbapenemase genes were detected (% Carb+)
Notable AMR STs by location
| Location | Total ESBL (%) | Total CP (%) | Notable clone/s | N ESBL (% of ESBL/site) | ESBL genes ( | CP genes ( | ||
|---|---|---|---|---|---|---|---|---|
| Hong Kong | 5 (19%) | 0 | – | – | – | – | – | – |
| Vietnam | 20 (25%) | 4 (5%) | * ST15 | 7 | 4 (20%) | CTX-M-15 (3) CTX-M-14 (2) | 2 (50%) | NDM-1 (1) |
| Thailand | 2 (50%) | 0 | – | – | – | – | – | – |
| Laos | 32 (53%) | 1 (2%) | * ST15 | 14 | 14 (44%) | CTX-M-15 (14) | 0 | – |
| ST76-1LV | 4 | 4 (13%) | CTX-M-15 (4) | 0 | – | |||
| Cambodia | 27 (64%) | 1 (2%) | ST20 | 5 | 5 (19%) | CTX-M-27 (3) CTX-M-14 (2) CTX-M-15 (1) | 0 | – |
| * ST15 | 3 | 3 (11%) | CTX-M-15 (3) CTX-M-27 (1) | 0 | – | |||
| ST36 | 3 | 3 (11%) | CTX-M-15 (2) | 0 | – | |||
| * ST15 | 8 | 8 (33%) | CTX-M-15 (8) | 6 (67%) | NDM-1 (5) | |||
| Nepal | 24 (75%) | 9 (28%) | ST4 | 5 | 5 (21%) | CTX-M-15 (5) | 0 | – |
| ST11 | 3 | 3 (13%) | SFO-1 (3) | 3 (33%) | OXA-232 (3) | |||
| India | 52 (61%) | 42 (49%) | ST231 | 17 | 13 (25%) | CTX-M-15 (13) | 13 (31%) | OXA-232 (13) |
| ST14 | 16 | 7 (13%) | CTX-M-15 (7) | 11 (26%) | OXA-232 (10) | |||
| * ST15 | 4 | 3 (6%) | CTX-M-15 (3) | 0 | – | |||
| ST16 | 3 | 3 (6%) | CTX-M-15 (3) | 2 (5%) | NDM-1 (1) | |||
| ST29 | 3 | 3 (6%) | CTX-M-15 (3) | 0 | – | |||
| ST395 | 3 | 1 (25%) | CTX-M-15 (1) | 3 (7%) | OXA-232 (3) |
Total ESBL and Total CP: total number of genomes carrying ESBL and carbapenemase genes per site, respectively
Notable clones: clones with ≥ 3 ESBL and/or carbapenemase gene-positive genomes at any single site. *ST15 is the only clone meeting these criteria at > 1 site
N: total number of genomes of each notable clone at each site (includes all genomes assigned to the ST regardless of predicted AMR)
N ESBL: number of genomes of each notable clone with at least one ESBL and no carbapenemase genes per site
ESBL genes: details of the ESBL genes detected in each notable clone at each site
N CP: number of genomes of each notable clone with at least one carbapenemase gene per site
CP genes: details of the carbapenemase genes detected in each notable clone at each site
Fig. 4Prevalence of key virulence determinants among K. pneumoniae sensu stricto isolates. a Proportion of genomes for which the yersiniabactin locus was detected (% ybt+) by location. b Proportion of genomes for which the aerobactin locus was detected (% iuc+) by location. c iuc lineages by location. Points are scaled by the number of genomes as per legend. Unk; unknown
Notable iuc-positive STs by region
| Location | Total | Notable clone/s | ICE | ESBL/CP ( | ||||
|---|---|---|---|---|---|---|---|---|
| Hong Kong | 6 (22%) | ST45 | 1 (17%) | ICE | – | – | CTX-M-3 (1) | |
| Vietnam | 34 (43%) | * ST23 | 13 (38%) | ICE ICE | (10) | CTX-M-14 (1) | ||
| * ST25 | 2 (6%) | ICE | (2) | – | ||||
| 1 (3%) | – | (1) | – | |||||
| * ST65 | 2 (6%) | ICE | (2) | CTX-M-15, VEB-1 (1) | ||||
| Thailand | 0 | – | – | – | – | – | – | |
| Laos | 23 (38%) | * ST23 | 10 (44%) | ICE | (10) | CTX-M-63 (1) | ||
| * ST65 | 2 (6%) | ICE | (3) | – | ||||
| * ST86 | – | ICE | (3) | – | ||||
| ST592 | 10 (44%) | (3) | – | |||||
| Cambodia | 4 (10%) | – | – | – | – | – | – | – |
| Nepal | 3 (9%) | ST15 | 2 (67%) | ICE | – | (2) | CTX-M-15 (2) OXA-232 (1) | |
| India | 24 (28%) | ST231 | 12 (50%) | ICE | – | – | CTX-M-15 (8) OXA-232 (8) | |
| 2 (8%) | ICE | – | – | CTX-M-15 (2) OXA-232 (2) | ||||
| ST2096 | 3 (13%) | ICE | – | CTX-M-15 (2) | ||||
| * ST23 | 2 (8%) | ICE ICE | (1) | CTX-M-15 (1) | ||||
| ST11 | 1 (48%) | ICE | – | – | CTX-M-15, OXA-232 (1) |
Total iuc+: total number of genomes carrying iuc per site (i.e. predicted as aerobactin-producing)
Notable clones: clones with ≥ 3 iuc-positive genomes at any single site, or carrying iuc in addition to ESBL and/or carbapenemase genes. *Known hypervirulent STs
iuc allele: iuc lineages predicted by Kleborate. unk = iuc lineage unknown
N iuc: number of genomes of each notable clone carrying iuc per site
ICEKp: ICEKp variants and the number of genomes of notable clones carrying these variants per site. aICEKp10 carries ybt and clb
iro allele: iro lineage and the number of genomes of notable clones carrying these iro variants per site
rmpA/2: number of genomes of notable clones carrying the rmpA and/or rmpA2 loci per site
ESBL/CP: ESBL and carbapenemase genes detected among notable clones and the number of genomes carrying these genes per site
Fig. 5Convergence of virulence and antimicrobial resistance determinants. a Frequency of genomes carrying the yersiniabactin (ybt), colibactin (clb) and/or aerobactin (iuc) loci shown by ESBL and carbapenemase gene status. Bars are coloured by location as per legend. Grey shading indicates convergent isolates, i.e. those harbouring at least one ESBL and/or carbapenamase gene plus iuc with/without ybt and clb. b Chromosomal sequence types of convergent isolates. Bars are coloured by location as per legend
Multi-country clusters of strains sharing a recent common ancestor
| ST | Pairwise SNVs (mean)a | Locations | Sample ID | Year | ESBL/CP genes | ICEKp | Plasmid-borne virulence loci |
|---|---|---|---|---|---|---|---|
| ST17 | 33 | Cambodia | COMRU-KPN-BC-2014-21 | 2014 | – | Unk | – |
| Vietnam | CM3425 | 2015 | – | Unk | – | ||
| ST65 | 37–138b (89) | Laos | 1675485 | 2015 | – | ICE | |
| Laos | 1675477 | 2015 | – | ICE | |||
| Laos | 16114200 | 2016 | – | – | |||
| Cambodia | COMRU-KPN-BC-2015-7 | 2015 | – | ICE | |||
| ST86 | 69 | Vietnam | 270210–16361 | 2010 | – | ICE | |
| Laos | 1623415 | 2016 | – | ICE | |||
| ST101 | 73 | Cambodia | KPN239 | 2014 | CTX-M-15 | – | – |
| Laos | 1690095 | 2015 | CTX-M-15, CTX-M-27 | – | – | ||
| ST592 | 70–91 (80) | Laos | 1675487 | 2015 | – | ||
| Laos | 1675478 | 2015 | – | – | |||
| Vietnam | CM3560 | 2015 | – | – | |||
| ST14 | 82 | Hong Kong | V28 | 2016 | – | – | – |
| India | BA33569 | 2016 | – | – | – | ||
| ST15 | 0–202 (84)c | Nepal | 2427 | 2016 | CTX-M-15, OXA-232, NDM-1 | ICE | – |
| Nepal | 2455 | 2016 | CTX-M-15, OXA-232, NDM-1 | – | – | ||
| Nepal | 2703 | 2016 | CTX-M-15, OXA-232, NDM-1 | – | – | ||
| Nepal | 2725 | 2016 | CTX-M-15, OXA-232, NDM-1 | – | – | ||
| Nepal | 2557 | 2016 | CTX-M-15 | – | |||
| Nepal | 2579 | 2016 | CTX-M-15, OXA-232 | – | |||
| India | BA12537 | 2017 | CTX-M-15 | ICE | – | ||
| ST412 | 86 | Laos | 16112578 | 2016 | – | – | |
| India | BA2641 | 2017 | – | – |
Genomes were clustered at a threshold of ≤ 100 SNVs (i.e. all members of a cluster differ from at least one other member by fewer than 100 SNVs). Clusters comprising isolates from multiple countries are shown. Unk unknown. aPairwise SNV count; for clusters of size > 2 genomes the range and mean are shown. bCambodian isolate COMRU-KPN-BC-2015-7 differs from each of the Laos isolates by 67–96 SNVs. cIndian isolate BA12537 differs from each of the Nepalese isolates by 81–202 SNVs. dICEKp10 carries ybt and clb